Dawn™ is a blood-based test utilizing a simple blood-draw. Our technology requires a small volume of blood that will be analyzed in our CLIA-certified laboratory. We measure glycoproteins using our proprietary technology based on AI. Our AI allows us to discover and measure these never-before characterized biological signals. We measure the patient's biological makeup and decipher clear signals correlated with response outcomes. We currently have data to support Dawn™ in pancreatic cancer, lung cancer, melanoma, and are working on other cancers.